This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Inclusion Criteria:

• Current doctor's diagnosis of generalized anxiety disorder
• In need of psychiatric treatment
• Willingness to complete all aspects of the study

Exclusion Criteria:

• Current doctor's diagnosis of major depression
• History of schizophrenia or schizoaffective disorders
• Drug dependence within 2 months prior to study start

For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:

www.novartisclinicaltrials.com